Crescent and Kelun-Biotech swap cancer asset rights in double deal
The partnership includes regional rights to Crescent’s bispecific antibody and Kelun’s ADC.
Therapy Area
WHO backs use of GLP-1RAs for weight loss despite shortage warning
“Sharp” funding cuts disrupt PrEP access to millions of HIV patients
Dupixent gains chronic spontaneous urticaria indication in Europe
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
Regeneron’s Eylea franchise boosted by pair of FDA approvals
